



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	221301	ViroGuard
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	14/03/2014	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . ViroGuard

Product Type	Single Medicine Product	Effective Date	23/10/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support immune system health
Maintain/support healthy immune system function
Helps reduce occurrence of facial cold sores
Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.
Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral

Visual Identification

Active Ingredients

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Echinacea purpurea herb Juice dry	9.44 mg
Equivalent: Echinacea purpurea (Fresh)	425 mg
lysine hydrochloride	530.98 mg
Equivalent: lysine	425 mg
Melissa officinalis leaf Extract dry concentrate	107.14 mg
Equivalent: Melissa officinalis (Dry)	750 mg
zinc amino acid chelate	12.5 mg
Equivalent: zinc	2.5 mg

Other Ingredients (Excipients)

Gelatin
glycerol
hydrogenated vegetable oil
iron oxide black
iron oxide red
iron oxide yellow
lecithin
maltodextrin
purified water
silicon dioxide
Soya Oil
titanium dioxide
yellow beeswax

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary